Heron Neutron Medical, a subsidiary of semiconductor equipment supplier Hermes-Epitek, is set to list on Taiwan’s stock market in mid-September. Heron General Manager Leo Shen stated that by integrating patented technologies from National Tsing Hua University and Taiwan’s Industrial Technology Research Institute (ITRI), the company has developed a patented accelerator-based boron neutron capture therapy (AB-BNCT) device for cancer treatment. This device received medical device certification in 2024, making Heron the first certified manufacturer in Taiwan and the second worldwide.

Taiwanese automaker Yulon Motor Co. held an online investor briefing on August 20, 2025, where General Manager Kuo-Hsing Hsu addressed the impact of tariff uncertainty on the domestic auto industry. Despite mounting pressure, Hsu said Yulon swiftly activated contingency plans and moved to mitigate potential losses early on. The company is now aggressively pursuing new contract manufacturing opportunities, adopting a “lead-and-support” model that integrates local suppliers into multi-model, mixed-line production to enhance the competitiveness of Taiwan-made vehicles.

Despite ongoing uncertainty surrounding Taiwan’s import tariffs and excise tax policies, China Motor Corporation (CMC), a subsidiary of the Yulon Group, maintains its full-year sales target of 49,000 vehicles for 2025, including contract manufacturing. Speaking at an online investor conference on August 20, CMC Vice President and Spokesperson Chien Ching-Wu said the company will not revise its capacity plans or its scheduled plant shutdowns.